Pelthos Therapeutics Inc. Amortization of Debt Discount (Premium)
Pelthos Therapeutics Inc. (PTHS) reported Amortization of Debt Discount (Premium) of $432.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-08-13
- Pelthos Therapeutics Inc. amortization of debt discount (premium) for the quarter ending 2026-06-30 was $237.00K, a 43.64% increase year-over-year.
- Pelthos Therapeutics Inc. amortization of debt discount (premium) for the quarter ending 2026-03-31 was $195.00K, a 107.45% increase year-over-year.
- Pelthos Therapeutics Inc. amortization of debt discount (premium) for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Pelthos Therapeutics Inc. amortization of debt discount (premium) for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Pelthos Therapeutics Inc. amortization of debt discount (premium) for fiscal 2025 was $259.00K, a 62.57% decline from fiscal 2024.
- Pelthos Therapeutics Inc. amortization of debt discount (premium) for fiscal 2024 was $692.00K, a 267.85% increase from fiscal 2023.
- Pelthos Therapeutics Inc. amortization of debt discount (premium) for fiscal 2023 was $188.12K, a 33.96% increase from fiscal 2022.
- Pelthos Therapeutics Inc. amortization of debt discount (premium) for fiscal 2022 was $140.43K.
| Period end | Amortization of Debt Discount (Premium) | Amortization of Debt Discount (Premium) 0 month | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 3 month as first filed | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 6 month as first filed | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 9 month as first filed | Amortization of Debt Discount (Premium) 12 month | Amortization of Debt Discount (Premium) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $237.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-13 | $432.00K 10-Q · filed 2026-08-13 | $432.00K derived: sum of 3 quarters · filed 2026-08-13 | $432.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2026-03-31 | $195.00K 10-Q/A · filed 2026-08-13 | $195.00K derived: sum of 2 quarters · filed 2026-08-13 | $195.00K derived: sum of 3 quarters · filed 2026-08-13 | $360.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $165.00K derived: sum of 3 quarters · filed 2026-08-13 | $259.00K 10-K · filed 2026-03-19 | ||||||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $165.00K derived: sum of 2 quarters · filed 2026-08-13 | $259.00K 10-Q · filed 2025-11-13 | $335.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2025-06-30 | $165.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-13 | $259.00K 10-Q · filed 2026-08-13 | $258.89K 10-Q · filed 2025-08-13 | $335.00K derived: sum of 3 quarters · filed 2026-08-13 | $345.37K derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2025-03-31 | $94.00K 10-Q/A · filed 2026-08-13 | $94.21K 10-Q · filed 2025-05-13 | $170.00K derived: sum of 2 quarters · filed 2026-08-13 | $180.37K derived: sum of 3 quarters · filed 2026-08-13 | $180.37K derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2024-12-31 | $76.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $86.37K derived: sum of 2 quarters · filed 2026-03-19 | $86.37K derived: sum of 3 quarters · filed 2026-03-19 | $692.00K 10-K · filed 2026-03-19 | $692.02K 10-K · filed 2025-03-27 | |||||
| 2024-09-30 | $10.37K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $10.37K derived: sum of 2 quarters · filed 2025-11-13 | $616.00K 10-Q · filed 2025-11-13 | $615.93K 10-Q · filed 2024-11-13 | $737.33K derived: sum of 4 quarters · filed 2025-11-13 | |||||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $605.63K 10-Q · filed 2025-08-13 | $726.96K derived: sum of 3 quarters · filed 2025-08-13 | $744.63K derived: sum of 4 quarters · filed 2025-08-13 | ||||||
| 2024-03-31 | $605.63K 10-Q · filed 2025-05-13 | $726.96K derived: sum of 2 quarters · filed 2025-05-13 | $744.63K derived: sum of 3 quarters · filed 2025-05-13 | $762.10K derived: sum of 4 quarters · filed 2025-05-13 | ||||||
| 2023-12-31 | $121.33K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $139.00K derived: sum of 2 quarters · filed 2025-03-27 | $156.47K derived: sum of 3 quarters · filed 2025-03-27 | $188.12K 10-K · filed 2025-03-27 | ||||||
| 2023-09-30 | $17.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $35.14K derived: sum of 2 quarters · filed 2024-11-13 | $66.79K 10-Q · filed 2024-11-13 | |||||||
| 2023-06-30 | $17.47K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $49.12K 10-Q · filed 2024-08-13 | ||||||||
| 2023-03-31 | $31.65K 10-Q · filed 2024-05-15 | |||||||||
| 2022-12-31 | $140.43K 10-K · filed 2024-04-16 | |||||||||
| 2022-04-02 | $150.00K 10-K · filed 2025-03-27 | |||||||||
| 2022-02-04 | $150.00K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |